{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:16:11Z","timestamp":1778858171959,"version":"3.51.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1604,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1111\/j.1365-2133.2011.10213.x","type":"journal-article","created":{"date-parts":[[2011,1,11]],"date-time":"2011-01-11T00:39:34Z","timestamp":1294706374000},"page":"1091-1096","source":"Crossref","is-referenced-by-count":223,"title":["Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris"],"prefix":"10.1093","volume":"164","author":[{"given":"R.","family":"Gniadecki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Kragballe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.N.","family":"Dam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Skov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,4,11]]},"reference":[{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2133.2008.08673.x","article-title":"Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials","volume":"159","author":"Brimhall","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1529-8019.2009.01259.x","article-title":"Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?","volume":"22","author":"Alwawi","year":"2009","journal-title":"Dermatol Ther"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1001\/jama.288.22.2868","article-title":"Interventions to enhance patient adherence to medication prescriptions: scientific review","volume":"288","author":"McDonald","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00128071-200607040-00004","article-title":"Pharmionics in dermatology: a review of topical medication adherence","volume":"7","author":"Lee","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2008.03.045","article-title":"One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic","volume":"59","author":"Storm","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1345\/aph.1E398","article-title":"Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence","volume":"39","author":"Elliott","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB7|cit7","first-page":"329","article-title":"Biologic survival","volume":"8","author":"Noiles","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB8|cit8","first-page":"S205","article-title":"DANBIO: a nationwide registry of biological therapies in Denmark","volume":"23","author":"Hetland","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","article-title":"Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","article-title":"Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis","volume":"61","author":"Du Pan","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1136\/ard.2004.031476","article-title":"Treatment continuation in patients receiving biological agents or conventional DMARD therapy","volume":"64","author":"Zink","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/art.21570","article-title":"The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden","volume":"54","author":"Kristensen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB14|cit14","first-page":"2398","article-title":"The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis","volume":"33","author":"Gartlehner","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.7326\/0003-4819-148-2-200801150-00192","article-title":"Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis","volume":"148","author":"Donahue","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB16|cit16","first-page":"233","article-title":"Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data","volume":"22","author":"Cassano","year":"2008","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jaad.2007.11.011","article-title":"The effect of weight on the efficacy of biologic therapy in patients with psoriasis","volume":"58","author":"Clark","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000149970","article-title":"Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus","volume":"217","author":"Reich","year":"2008","journal-title":"Dermatology"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/j.1468-3083.2009.03325.x","article-title":"Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation","volume":"23","author":"Martyn-Simmons","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB20|cit20","first-page":"18","article-title":"Treatment of psoriasis with adalimumab","volume":"32","author":"Pitarch","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/archderm.144.6.804","article-title":"Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment","volume":"144","author":"Van","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/ard.2006.054742","article-title":"Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?","volume":"66","author":"Hjardem","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2133.2011.10213.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/rheumatology\/ken034","article-title":"Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register","volume":"47","author":"Karlsson","year":"2008","journal-title":"Rheumatology (Oxford)"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2011.10213.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2011.10213.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T08:51:11Z","timestamp":1676364671000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/164\/5\/1091\/6642990"}},"subtitle":["Adherence to treatment with biologics in patients with psoriasis"],"short-title":[],"issued":{"date-parts":[[2011,4,11]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10213.x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.11067956.14692058","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.11067956.12021054","asserted-by":"object"}]},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4,11]]}}}